Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BPTF | Q12830 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 8/20 | 0.44 |
| ▸ | HTR2B | P41595 | 8/20 | 0.44 |
| ▸ | HTR2A | P28223 | 7/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3886033 | 0.77 | BPTF (0.45) | BPTFHTR2CHTR2BHTR2ACHRNB2 | |
| SCHEMBL3886031 | 0.77 | BPTF (0.45) | BPTFHTR2CHTR2BHTR2ACHRNB2 | |
| SCHEMBL3886029 | 0.77 | BPTF (0.45) | BPTFHTR2CHTR2BHTR2ACHRNB2 | |
| SCHEMBL3887869 | 0.77 | BPTF (0.45) | BPTFHTR2CHTR2BHTR2ACHRNB2 | |
| SCHEMBL6646375 | 0.72 | GRIN2B (0.55) | HTR2CHTR2BHTR2AGRIN2BALDH1A1 | |
| SCHEMBL4696472 | 0.72 | ALDH1A1 (0.49) | GRIN2BCHRNA7CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL24490876 | 0.71 | CCR5 (0.44) | BPTFCHRNA7CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL17304817 | 0.71 | GRIN2B (0.44) | HTR2AGRIN2BALDH1A1KDM4ENPSR1 | |
| Hydrochloric Acid SCHEMBL2224880 | 0.71 | HPGD (0.54) | HTR2CHTR2BHTR2AGRIN2BALDH1A1 | |
| SCHEMBL17294969 | 0.71 | GRIN2B (0.44) | HTR2AGRIN2BALDH1A1KDM4ENPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204224-A1 | AZACYCLIC COMPOUNDS AS INHIBITORS OF SENSORY NEURONE SPECIFIC SODIUM CHANNELS | VERNALIS R & D LIMITED (GB) | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204224-A1 | AZACYCLIC COMPOUNDS AS INHIBITORS OF SENSORY NEURONE SPECIFIC SODIUM CHANNELS | SCN1B, SCN2B, SCN1A | BPTF 3835/4885HTR2C 496/4885HTR2B 314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.